The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I clinical trial of trametinib in combination with TAS-102 in patients with chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-wild type) metastatic colorectal cancer.
 
Jeremy Chuang
No Relationships to Disclose
 
Jun Gong
Honoraria - Amgen; Astellas Pharma; AVEO; Basilea Pharmaceutical; Bayer; Clinical Congress Consultants; Elsevier; EMD Serono; Exelixis; HalioDx; Janssen Biotech; Natera; QED Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; Clinical Congress Consultants; Elsevier; Exelixis; QED Therapeutics
 
Sierra Li
No Relationships to Disclose
 
Chongkai Wang
No Relationships to Disclose
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; GlaxoSmithKline; Incyte; Pfizer; Seagen; Taiho Pharmaceutical; Zhuhai DL Biotech
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)